Critical Survey: Gilead Sciences (NASDAQ:GILD) and Pharvaris (NASDAQ:PHVS)

Gilead Sciences (NASDAQ:GILD) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation and Earnings

This table compares Gilead Sciences and Pharvaris”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44 billion	5.83	$8.51 billion	($2.67)	-51.82
Pharvaris	N/A	N/A	-$198.79 million	($3.18)	-11.05

Gilead Sciences has higher revenue and earnings than Pharvaris. Gilead Sciences is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Pharvaris’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Pharvaris	N/A	-61.40%	-56.00%

Insider & Institutional Ownership

83.7% of Gilead Sciences shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.31, suggesting that its share price is 331% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Gilead Sciences and Pharvaris, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0	5	24	0	2.83
Pharvaris	1	2	11	1	2.80

Gilead Sciences currently has a consensus price target of $158.04, suggesting a potential upside of 14.22%. Pharvaris has a consensus price target of $51.08, suggesting a potential upside of 45.35%. Given Pharvaris’ higher probable upside, analysts clearly believe Pharvaris is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Pharvaris on 9 of the 14 factors compared between the two stocks.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.